Stocks · News reference
Avalyn Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
Avalyn Pharma announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline, including the initiation of a Phase 1 study for AP03.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — Avalyn Pharma Inc. (AVLN)
Filed: 2026-11-12 AccNo: 0001193125-26-457053 Size: 309 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Avalyn Pharma Announces Participation in Upcoming Investor Conferences
Avalyn Pharma Inc. announced its scheduled participation in three upcoming investor conferences in November and December 2026.
This Enliven Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Analysts initiated coverage: VYLR Outperform/$85, LBRX Buy/$68, ELVN Overweight/$70, SAIL Sector Weight, and AVLN Outperform/$60.
Raymond James Initiates Coverage On Avalyn Pharma with Outperform Rating, Announces Price Target of $60
Avalyn Pharma Says Respiratory Research Publishes Detailed Results From Two Phase 1 Clinical Trials Of AP02 In Healthy Volunteers And Patients With IPF, Validating Inhaled Antifibrotic Approach
Results validate Avalyn’s approach of delivering established antifibrotic medicines directly to the lungs to maximize local exposure while limiting systemic exposure and improving tolerabilityFindings support continued